Compare YieldMax NVDA Option Income Strategy ETF (NVDY) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax NVDA Option Income Strategy ETF vs Novartis AG — how do they compare? YieldMax NVDA Option Income Strategy ETF trades at $12.59, while Novartis AG trades at $153.88 (market cap $290.25B). The key difference: Novartis AG pays a 3.17% dividend while YieldMax NVDA Option Income Strategy ETF pays none, and Novartis AG is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| NVDY | NVS | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $17.96 | $168.62 |
52-Week Low | $12.03 | $113.50 |
Market Cap | — | $290.25B |
Enterprise Value | — | $330.27B |
Dividend Yield | — | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDY (YieldMax NVDA Option Income Strategy ETF) trades at $12.41, showing modest daily gains of 0.4%. The ETF employs a covered call strategy on NVIDIA shares, generating weekly distributions but capping upside potential. Technical indicators signal bearish momentum with moving averages and ADX pointing downward, while oscillators remain neutral. Recent distributions have ranged from $0.10 to $0.21 per share, providing income-focused investors with regular cash flow.
The outlook remains challenging as the covered call strategy sacrifices NVIDIA's explosive growth potential for income generation. Key risks include opportunity cost from missed upside, fund management fees, and dependence on NVIDIA's volatility. While attractive for income seekers, growth-oriented investors may prefer direct NVIDIA exposure given the significant performance trade-off.
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
